Alnylam price target raised to $535 from $459 at Truist

TipRanks

Sat, October 18, 2025 at 9:05 AM EDT 1 min read

Truist raised the firm’s price target on Alnylam (ALNY) to $535 from $459 and keeps a Buy rating on the shares ahead of its Q3 results. The firm has increased its Q3 Amvuttra sales estimate to $690M and also revised its forward estimates higher to reflect carry through from the strong early adoption and more rapid adoption as a first line agent than previously expected based on feedback from prescribers in the quarter who indicated extracardiac manifestations of ATTR-CM are more widespread than previously appreciated, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas” href=”https://www.tipranks.com/screener/analysts-top-stocks/?type=stockAnalysisLanding&utm_source=finance.yahoo.com&utm_medium=referral” rel=”nofollow noopener” target=”_blank”>See the top stocks recommended by analysts >>